Advertisement


David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

2025 ASCO Annual Meeting

Advertisement

David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, reviews data on the role of a 14-gene molecular assay in selecting patients with stage IA–IIA non–small cell lung cancer (NSCLC) as high risk (LBA8027). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We are discussing a trial we presented here at ASCO. It's a late-breaking abstract. It's called the AIM-HIGH study. The goal of this trial was to see if we could help patients with early-stage lung cancer live longer without their cancer coming back. Early-stage lung cancer is certainly a setting where we want to cure patients, and historically we divide early stages into stages 1, 2, and 3. Lung cancer, non-small cell lung cancer, and chemotherapy is an established treatment in stage 2 and in 3 disease after surgery, and stage 1 and in some stage 2 cancers. It's still something you can be on the fence as a provider in terms of whether a patient really benefits from it or needs it. Could there be a way to better assess a patient's risk for cancer coming back and apply an intervention like chemotherapy to the higher-risk patient and maybe not to the lower-risk patient? This strategy is already pretty common in breast cancer care and in colon cancer and prostate cancer care. And so this study employed a molecular classifier. It's a 14-gene expression assay from a company called Razor Genomics. This assay was already prospectively validated in over 1500 patients in two single-cohort trials close to 10 years ago. But this is a randomized trial we presented using that assay. And so here's how it went. Patients had non-squamous, non-small cell lung cancer. The assay was validated on non-squamous histology. Everybody had stage 1A, 1B, and 2A non-small cell lung cancer. Everybody had surgery, and then after surgery the tumor was assessed using this 14-gene classifier, and the results came back in about 10 days and you were scored as a low risk, intermediate, or high risk. If you had a low-risk score, you didn't need any additional intervention. We know from those earlier cohorts that there's over a 95% chance of being cured if you're a low-risk early-stage cancer. But if you were in the intermediate or high-risk score, you entered the study and you were randomized to 4 cycles of adjuvant platinum doublet chemotherapy—something we were routinely using in stage 2 and 3 disease—or to observation. The study was designed to look at an endpoint called disease-free survival, how long you live without cancer coming back. And so the study started and then was stopped early. The data safety monitoring board said there's already a dramatic result and this trial should stop early, and hence why we presented as a late breaker. So a little under 100 patients were in the experimental arm—that is, patients with intermediate or high-risk scores who received chemotherapy. And then a little over 100 patients were in the control arm when the trial was stopped. And the reason it was stopped was because of the overwhelming advantage in favor of the patients who got chemotherapy. So those patients that were intermediate and high risk who got chemo had an absolute advantage in terms of disease-free survival at 24 months. Specifically, the hazard ratio was 0.22. In other words, there was a 78% reduction in the risk of cancer coming back or dying if you'd gotten chemotherapy. And so that's where we're at. This assay is already available, and I think where we're at now is a patient walks into the clinic, has had surgery, has stage 1A, 1B, and even 2A non-small cell lung cancer. If you know that chemotherapy is what you recommend based on everything you know about the patient and they want that, this test is not for them. If you know you don't want to do it for whatever reason—you know chemo's not, maybe a patient comes into it saying they don't want it. No matter what you say, there are certain scenarios like that. This test is not for them either. But for those patients who are like, should I do more? I'm not sure. I have an early-stage cancer. I'm on the fence about chemo. This risk classifier can help patients be armed with information and their providers to say, hey, I have a low-risk cancer, I can feel pretty good about not doing anything more. Or I have an intermediate or high-risk cancer where chemotherapy could help dramatically—close to 80% improvement in my risk reduction for cancer returning or dying from cancer. And so I think this is a big step forward and certainly something doctors and patients and their families are going to want to use to help plan their treatment.

Related Videos

Genomics/Genetics

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579). 

Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Breast Cancer

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).  

Lung Cancer

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 

Head and Neck Cancer

Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at high risk of relapse (LBA2). 

Advertisement

Advertisement




Advertisement